. PGE2 stimulates human brain natriuretic peptide expression via EP4 and p42/44 MAPK. Am J Physiol Heart Circ Physiol 290: H1740 -H1746, 2006. First published January 20, 2006 doi:10.1152/ajpheart.00904.2005.-Brain natriuretic peptide (BNP) produced by cardiac myocytes has antifibrotic and antigrowth properties and is a marker of cardiac hypertrophy. We previously showed that prostaglandin E2 (PGE2) is the main prostaglandin produced in myocytes treated with proinflammatory stimuli and stimulates protein synthesis by binding to its EP4 receptor. We hypothesized that PGE2, acting through EP 4, also regulates BNP gene expression. We transfected neonatal ventricular myocytes with a plasmid encoding the human BNP (hBNP) promoter driving expression of a luciferase reporter gene. PGE2 increased hBNP promoter activity 3.5-fold. An EP 4 antagonist reduced the stimulatory effect of PGE2 but not an EP1 antagonist. Because EP4 signaling can involve adenylate cyclase, cAMP, and protein kinase A (PKA), we tested the effect of H-89, a PKA inhibitor, on PGE2 stimulation of the hBNP promoter. H-89 at 5 M decreased PGE2 stimulation of BNP promoter activity by 100%. Because p42/44 MAPK mediates the effect of PGE2 on protein synthesis, we also examined the role of MAPKs in the regulation of BNP promoter activity. PGE2 stimulation of the hBNP promoter was inhibited by a MEK1/2 inhibitor and a dominant-negative mutant of Raf, indicating that p42/44 MAPK was involved. In contrast, neither a p38 MAPK inhibitor nor a JNK inhibitor reduced the stimulatory effect of PGE2. Involvement of small GTPases was also studied. Dominant-negative Rap inhibited PGE2 stimulation of the hBNP promoter, but dominant-negative Ras did not. We concluded that PGE2 stimulates the BNP promoter mainly via EP4, PKA, Rap, and p42/44 MAPK. EP receptor; cardiac myocytes; hypertrophy; signaling pathways BRAIN NATRIURETIC PEPTIDE (BNP), one of three members of the natriuretic peptide family, is a cardiac hormone composed of 32 amino acids (in the human heart) and has diuretic, natriuretic, vasodilator, and antifibrotic properties (22). BNP is synthesized and secreted constitutively by the adult heart (primarily the ventricle) (2, 35). It is also regarded as a marker gene of hypertrophy. Circulating levels of BNP are elevated as a result of myocardial infarction (MI), hypertrophy, or heart failure (1, 35). Plasma BNP concentrations also serve as a biochemical marker of left ventricular dysfunction and a neuroendocrine marker of heart failure (24, 40). Patients with heart failure infused with BNP have reduced preload and afterload, increased stroke volume, and enhanced natriuresis and diuresis (3); thus it would appear that this cardiac hormone has beneficial and compensatory effects that modulate the progression of cardiac dysfunction. For example, BNP has antifibrotic actions in the heart (16, 31, 44). It may also have antigrowth actions in the vasculature, operating either directly or indirectly through stimulation of C-type natriuretic peptide synthesis (33, 37, 38) .
BRAIN NATRIURETIC PEPTIDE (BNP), one of three members of the natriuretic peptide family, is a cardiac hormone composed of 32 amino acids (in the human heart) and has diuretic, natriuretic, vasodilator, and antifibrotic properties (22) . BNP is synthesized and secreted constitutively by the adult heart (primarily the ventricle) (2, 35) . It is also regarded as a marker gene of hypertrophy. Circulating levels of BNP are elevated as a result of myocardial infarction (MI), hypertrophy, or heart failure (1, 35) . Plasma BNP concentrations also serve as a biochemical marker of left ventricular dysfunction and a neuroendocrine marker of heart failure (24, 40) . Patients with heart failure infused with BNP have reduced preload and afterload, increased stroke volume, and enhanced natriuresis and diuresis (3); thus it would appear that this cardiac hormone has beneficial and compensatory effects that modulate the progression of cardiac dysfunction. For example, BNP has antifibrotic actions in the heart (16, 31, 44) . It may also have antigrowth actions in the vasculature, operating either directly or indirectly through stimulation of C-type natriuretic peptide synthesis (33, 37, 38) . PGE 2 is a proinflammatory prostanoid that acts as an autocrine/paracrine mediator to signal changes within the immediate environment where it is released. It is synthesized from arachidonic acid by cyclooxygenase (COX-1 and COX-2) and PGE 2 synthase (25) . In cardiac myocytes, induction of COX-2 by the proinflammatory cytokine interleukin-1␤ was accompanied by induction of the PGE 2 synthase mPGES-1, resulting in the release of micromolar amounts of PGE 2 (11) . PGE 2 has growth-promoting effects in many cell types, most notably colorectal carcinoma cell proliferation and migration (36) . We previously showed that exogenous PGE 2 increased protein synthesis in myocytes, a marker of hypertrophic growth (26) . Moreover, in a mouse model of myocardial infarction, inhibition of COX-2 decreased myocyte cross-sectional area, an index of hypertrophy (19) . In addition to regulation of protein synthesis, PGE 2 also stimulated synthesis and secretion of atrial natriuretic peptide (ANP) (10) and ANP promoter activity in myocytes (27) ; however, no signaling mechanisms were identified in those studies. Thus, in the present study, we focused on the intracellular mechanisms involved in PGE 2 regulation of BNP gene expression. PGE 2 exerts its biological actions through four specific heteromeric G protein-coupled receptors (GPCRs), EP 1 , EP 2 , EP 3 , and EP 4 , which differ in structure, ligand-binding properties, activation of signal transduction pathways, and tissue distribution (32) . The mRNAs for EP 2 , EP 3 , and EP 4 have been detected in the heart of several species, including humans, and EP 4 is the most abundantly expressed EP subtype (47) . EP 1 is linked to a G q ␣ protein and its activation results in Ca 2ϩ mobilization; the EP 3 receptor is coupled to a G i ␣ protein, leading to decreased cAMP levels. Activation of EP 4 and EP 2 leads to accumulation of intracellular cAMP through interaction with a cholera-sensitive G s ␣ protein. EP 4 has also been linked to activation of p42/44 MAPK (4), and in cardiac myocytes it is involved in regulation of protein synthesis (27) . Because the role of EP 4 signaling pathways in the regulation of gene expression in cardiac myocytes has not been investigated to our knowledge, this was the focus of the present study.
METHODS
Cell culture. Preparation of neonatal ventricular myocytes (NVM) from rat pups was approved by the Henry Ford Hospital Institutional Animal Care and Use Committee. Primary cultures of NVM were derived from digestion of hearts from 1-to 2-day-old neonatal Sprague-Dawley rats (Charles River Laboratories, Kalamazoo, MI) as described previously (20) . NVM were placed in 12-well plates (0.5 ϫ 10 6 cells/well) or 10-cm plates (6 ϫ 10 6 cells) and cultured in DMEM (GIBCO) containing 100 U/ml penicillin, 100 g/ml streptomycin, 2 mmol/l glutamine, 0.1 mmol/l bromodeoxyuridine, and 10% FBS (HyClone) for 40 h. They were maintained in serum-free DMEM (SF-DMEM plus penicillin, streptomycin, glutamine, insulin, transferrin, and selenium) for 24 h before adding test compounds.
Transient transfection and luciferase activity assay. Transfection and luciferase activity assay were described previously (21) . Briefly, freshly isolated NVM were transiently transfected by electroporation in PBS-glucose at 0.28 V and 250 F with a Bio-Rad gene pulser. One microgram of 1818hBNPLuc [a plasmid encoding the hBNP promoter (from position Ϫ1818 to ϩ100) driving expression of a luciferase reporter gene] (21), ⌬73Luc (the same DNA construct as 1818hBNPLuc but without the hBNP promoter), or CRE-luciferase (2 cAMP and PKA-responsive elements cloned upstream from a minimal thymidine kinase-driven luciferase reporter; Clontech) was transfected per 10 6 cells. To test the effect of the dominant-negative mutants of Raf (dnRaf), Ras (dnRas), and Rap (dnRap) on hBNP promoter activity, 1818hBNPLuc (0.33 g/10 6 cells) was cotransfected with dnRaf, dnRas, dnRap (3.3 g/10 6 cells), or a control vector. Forty hours after transfection and incubation in 10% FBS-DMEM, the cells were starved in SF-DMEM for 24 h and then treated with PGE 2 or other agents for 24 h. Effects of pharmacological inhibitors were tested by treating cells for 1 h before addition of PGE2. Finally, NVM were harvested, lysed, and assayed for luciferase activity (relative light units or RLU) with the Promega luciferase assay system and an OptoComp 1 luminometer (MGM) according to the manufacturer's protocol. Duplicate aliquots of cell lysates from triplicate wells were averaged. Sample protein concentrations were also assayed using Coomassie protein reagent (Pierce).
DNA constructs. The chimeric hBNP-luciferase reporter gene construct (1818hBNPLuc) has been described previously (21) . dnRaf (Raf 301) and dnRas (Ras N17) were obtained from Dr. Michael Karin (Univ. of California at San Diego). dnRap (Rap N17) was obtained from Dr. M. Olah (Univ. of Cincinnati Medical School). The generation and efficacy of these constructs have been described previously (5, 9, 17) . Western blot analysis of NVM transfected with dnRas and dnRap showed that protein levels were increased 12 Ϯ 4.4-fold and 8.8 Ϯ 1.9-fold, respectively.
Chemicals. PGE2, butaprost (EP 2 agonist), sulprostone (EP1/EP3 agonist), and SC-19220 (EP1 antagonist) were from Cayman. L-161982 (EP4 antagonist) was provided by Merck-Frosst (gift of Dr. Robert Young). U-0126 (MEK1/2 inhibitor), SB-203580 (p38 MAPK inhibitor), and SP-600125 (JNK inhibitor) were purchased from Calbiochem, and H-89 (PKA inhibitor) was from Biomol. Effective concentrations of these chemicals were either determined in our laboratory or obtained from the literature (11, 27, 46) . Other standard laboratory supplies and reagents were obtained from Fisher, VWR, Promega, and Sigma.
Analysis of BNP mRNA by real-time PCR. We analyzed BNP and ␤-actin mRNA by real-time RT-PCR, which produced cDNAs of 241 bp (BNP) and 342 bp (␤-actin). PCR conditions and the sequences of primers and probes were reported previously (19) . In brief, total RNA of NVM was extracted in Tri-Reagent (MRC) according to the manufacturer's instructions. After treating the samples with DNase I and reverse transcription, we performed real-time PCR using a QuantiTect Probe PCR kit (Qiagen) and a Roche LightCycler (version 2.0). Data analysis was performed with LightCycler software (version 4.0). Gene-specific standard curves were generated using a linearized plasmid containing the cDNA of interest and serially diluting it to generate concentrations ranging over five orders of magnitude. The LightCycler software calculates the amount of cDNA in a given sample (copies/l) compared with the standard curve. BNP cDNA was normalized to ␤-actin cDNA.
Statistical analysis. Luciferase activity from each sample was normalized to its protein levels (RLU/mg protein). Control values were arbitrarily set to 1.0 and compared with other treatment groups to determine the fold increase. Data are expressed as means Ϯ SE and were analyzed either by Student's t-test or by 1-way ANOVA, with multiple pairwise comparisons made by the Student-Newman-Keuls method. P Ͻ 0.05 was considered significant. 4 receptor. To determine whether PGE 2 stimulates the hBNP promoter, we measured luciferase activity in lysates of transiently transfected NVM. As indicated in Fig. 1A , PGE 2 increased hBNP promoter activity in a dose-dependent manner at 1.0 and 5.0 M. However, 1 M PGE 2 had no effect on the promoterless construct (control ϭ 1-fold; PGE 2 ϭ 1.2 Ϯ 0.1-fold; n ϭ 4; P ϭ NS).
RESULTS

PGE 2 activates the hBNP promoter via the EP
We next investigated the involvement of EP 4 in stimulation of the hBNP promoter using L-161982, an EP 4 antagonist. L-161982 (10 M) reduced the stimulatory effect of PGE 2 to a level not statistically different from control (Fig. 1B) , suggesting that EP 4 plays a major role in the effect of PGE 2 . To test the specificity of the EP 4 antagonist, we examined its effect on stimulation of the hBNP promoter by sulprostone (a metabolism-resistant EP 3 agonist), using a concentration that had a stimulatory effect similar to 1 M PGE 2 . Treatment with 0.1 M sulprostone stimulated hBNP promoter activity 2.1-fold, which was unaffected by the EP 4 antagonist (Fig. 1C) .
PGE 2 increases BNP mRNA. To confirm that BNP promoter activity represented an increase in BNP transcription, we used real-time RT-PCR to investigate the effects of PGE 2 on BNP mRNA. Treating NVM with 1 M of PGE 2 for 4 h increased BNP mRNA 2.2-fold (Fig. 2) . Agarose gel electrophoresis of the PCR products revealed cDNA fragments of the correct size (BNP, 241 bp; ␤-actin, 342 bp; data not shown).
EP 1 and EP 2 are not involved in hBNP promoter activation. Because PGE 2 can bind to all four EP receptors (EP 1-4 ) (32), we investigated the effects of other EP agonists and antagonists. As shown in Fig. 3A , the EP 1 antagonist SC-19220 (10 M) had no effect on PGE 2 -stimulated luciferase activity. To test EP 2 involvement, we used the EP 2 agonist butaprost (0.01 to 10 M) but found that it had no effect on hBNP promoter activity (Fig. 3B) . As a control, we tested the efficacy of 1 M butaprost by measuring cAMP generation (26) . After stimulation with butaprost for 30 min, there was a fourfold increase in intracellular cAMP (from 0.44 Ϯ 0.16 to 1.92 Ϯ 0.1 pmol/5 ϫ 10 5 cells; n ϭ 3; P Ͻ 0.001). Together these data suggest that neither EP 1 nor EP 2 is involved in PGE 2 stimulation of the hBNP promoter.
PGE 2 stimulation of the hBNP promoter involves PKA. EP 4 can couple to cAMP-PKA pathways through G s ␣ protein (39), and PGE 2 increases cAMP in cardiac myocytes (26) . In addition, cAMP-dependent activation of PKA may result in subsequent growth-promoting signaling pathways (48) . Hence, we examined whether the traditional cAMP-PKA pathway mediates PGE 2 stimulation of the hBNP promoter. We first tested the efficacy of H-89 using CRE-luciferase (CRE-Luc), which contains a binding site for CRE binding protein (CREB), a cAMP-and PKA-activated transcription factor. Forskolin (10 M), an activator of adenylate cyclase, stimulated CRE-Luc twofold, while 5 M H-89 inhibited the effect by 100% (Fig.  4A) . The promoterless construct was not responsive to forsko- lin (data not shown). Additionally, we found that 1 M H-89 did not affect PGE 2 stimulation of the hBNP promoter (Fig.  4B) (27) and that p38 MAPK is involved in regulation of the hBNP promoter by many different stimuli (18) . In addition, a study of EP 4 -overexpressing cells has indicated that EP 4 couples to growth-promoting pathways (8). Thus we tested the roles of the three MAPK signaling cascades in PGE 2 regulation of BNP promoter activity. We first studied whether PGE 2 activates p42/44 MAPK and confirmed our previous study (27) showing that stimulation of NVM with PGE 2 for 5 min enhanced p42/44 MAPK phosphorylation (data not shown). When we administered the MEK1/2 inhibitor U-0126 (10 M), PGE 2 stimulation of the hBNP promoter was significantly inhibited (Fig. 5A) . To verify this finding, we investigated the effect of Raf, an upstream activator of MEK1/2. As shown in Fig. 5B , dnRaf also inhibited the effect of PGE 2 , confirming that p42/44 MAPK mediates hBNP promoter activation. In contrast, neither the p38 MAPK inhibitor SB-203580 (10 M) (Fig. 6A) nor SP-600125 (10 M), a JNK inhibitor, was able to block PGE 2 stimulation of the hBNP promoter. Paradoxically, JNK inhibition enhanced the effect of PGE 2 (Fig. 6B) .
The small GTPase Rap is involved in the effect of PGE 2 . Either Rap or Ras can activate Raf, thereby stimulating p42/44 MAPK (12, 17) . We tested the involvement of these small GTPases in PGE 2 stimulation of the BNP promoter. dnRap inhibited PGE 2 stimulation of the hBNP promoter by 42% (n ϭ 4, P Ͻ 0.05) (Fig. 7A) , but dnRas had no effect (Fig. 7B) . Overexpression of dnRap and dnRas was confirmed by Western blot, as reported in METHODS.
DISCUSSION
BNP is an antifibrotic hormone and a marker gene of cardiac hypertrophy (15) . It is also a good predictor of left ventricular dysfunction and is used to treat acute heart failure (1, 3, 24, 35, 40) . Hence, investigation of the signaling pathways that regulate BNP expression may improve our understanding of the underlying mechanisms of cardiac hypertrophy and heart failure. Many prohypertrophic and proinflammatory molecules regulate BNP gene expression (18) . PGE 2 is a well-known inflammatory mediator and growth factor, acting through EP [1] [2] [3] [4] receptors. We have shown that PGE 2 is the main prostaglandin released by interleukin-1␤-stimulated cardiac myocytes and increases protein synthesis and cell size by EP 4 and p42/44 MAPK (26) . Therefore, it is reasonable to expect that PGE 2 regulates BNP expression via similar pathways. Indeed, in the present study we found that PGE 2 stimulates the hBNP promoter through activation of EP 4 . Because PGE 2 stimulated the BNP promoter and mRNA to a similar extent (ϳ2-to 3-fold), we believe this stimulation occurs at the transcriptional level.
EP receptors are GPCRs, a seven-transmembrane domain receptor family coupled to heteromeric G proteins. So far, four EP receptors have been described, which couple to different intracellular signaling cascades (32) . EP 1 is linked to G q ␣ and elevated intracellular calcium levels, and EP 3 couples to G i ␣ and decreased cAMP, whereas EP 2 and EP 4 are coupled to G s ␣ and result in increased cAMP (32) . Although EP 2 and EP 4 are both linked to G s ␣, there are significant differences in their signaling capabilities. For example, in cells overexpressing EPs, EP 2 couples to PKA-dependent signaling cascades (6, 39) . In contrast, EP 4 binding to PGE 2 produces less cAMP (7) and results in rapid internalization linked to downstream activation of p42/44 MAPK (4, 8), similar to the ␤ 2 -adrenergic receptors.
Our pharmacological approach showed that EP 1 and EP 2 do not mediate PGE 2 stimulation of the hBNP promoter. This supports our previous finding that a selective inhibitor of the EP 1 and EP 2 receptor subtypes does not affect PGE 2 stimulation of protein synthesis in NVM (26) . EP 4 plays a major role in PGE 2 regulation of BNP expression, because the EP 4 antagonist inhibited PGE 2 stimulation of the hBNP promoter. In agreement with these data, we have found that PGE 2 treatment of cardiac myocytes increases protein synthesis and cell size mainly through EP 4 (27) . Moreover, EP 4 is involved in growth of other cell types. In models of colon cancer, either knockout or inhibition of EP 4 decreased cancer growth (30) . Because the EP 4 antagonist did not completely inhibit PGE 2 stimulation of the hBNP promoter, it is possible that another EP subtype plays a minor role. The EP 3 agonist sulprostone stimulated hBNP promoter activity, but at 0.1 M it did not activate EP 4 . Thus EP 3 may play a minor role in BNP gene regulation. We are in the process of developing an EP 4 small interfering RNA to confirm our findings.
EP 4 has been shown to couple to the cAMP-PKA cascade. cAMP can modulate cell growth, depending on the cell type (43) . Although PGE 2 resulted in cAMP production by myocytes (26) , neither PGE 2 stimulation of protein synthesis (27) nor isoproterenol regulation of the hBNP promoter (14) was affected by 1 M H-89. In accord with our previous data, 1 M H-89 had no effect on PGE 2 stimulation of the hBNP promoter in the present study. In contrast, 5 M H-89 reduced the effect of PGE 2 by 100%. An examination of the hBNP 5Ј-flanking sequence for potential CRE sites (TGACGTCA) found no consensus elements, although there was a partial site (CTTCGTCA) located at Ϫ839 (21). This might suggest an indirect effect of PKA on the BNP promoter or nonspecific effects of H-89 at high concentrations. Nonetheless, using EP 2 -and EP 4 -overexpressing HEK cells, investigators have demonstrated differences between the two receptors in cAMP production, PKA dependence, and signaling to downstream effectors (e.g., Tcf/Lef and CREB) (6, 7) . Thus it appears that EP 4 signaling may be distinct in different cell types.
MAPK cascades are among the most thoroughly studied signal transduction systems and play critical roles in cell differentiation, growth, and apoptosis as well as regulation of various transcription factors and gene expression (42) . In mammalian systems, the family is composed of three distinct MAPK modules. These include the p42/44 MAPK (ERK1/2) cascade, which preferentially regulates cell growth and differentiation, as well as the JNK and p38 MAPK cascades, which function mainly in stress responses like inflammation and apoptosis (41) . We demonstrated here that PGE 2 stimulated p42/44 MAPK phosphorylation. Inhibition of p42/44 MAPK using both a p42/44 MAPK inhibitor and dnRaf blocked PGE 2 stimulation of hBNP promoter activity. In accordance with our results, p42/44 MAPK has been implicated in GPCR-dependent regulation of cardiac hypertrophy both in vivo and in vitro (27) .
In contrast to p42/44 MAPK, p38 MAPK involvement in cardiac hypertrophy is uncertain. p38 MAPK mediated the hypertrophic effects of a variety of other GPCR agonists (34) , but in genetically modified animal models p38 MAPK did not mediate cardiac hypertrophy in vivo (49) . Our study showed that p38 MAPK is not involved in PGE 2 stimulation of the hBNP promoter. We also investigated the role played by JNK. A JNK inhibitor, SP-600125, did not inhibit PGE 2 stimulation of the hBNP promoter but rather enhanced it, suggesting that there may be cross-talk between p42/44 MAPK and JNK, as MAPKs have been reported to oppose each other in regulating ANP expression (34) . Thus we hypothesized that activation of JNK would in turn inactivate p42/44 MAPK and that JNK inhibition would reverse this process, allowing for enhanced activation of p42/44 MAPK. However, in preliminary studies we found no effect of the JNK inhibitor on PGE 2 activation of p42/44 MAPK (Qian J-Y and LaPointe MC, unpublished observations). Thus this observation with the JNK inhibitor requires further study.
Presently, we have not completely clarified how EP 4 links to p42/44 MAPK activation. In cells overexpressing EP 4 , activation of p42/44 MAPK is mediated by ␤-ARK, ␤-arrestin, Src, and small GTPases (23) . The small GTPases Ras and Rap1 have different functions. Ras acts through Raf-1 to activate MEK and p42/44 MAPK, while Rap1 acts via B-Raf. The second messenger cAMP can activate Rap1 either via a cAMPdependent exchange factor (Epac) or a cAMP-PKA pathway (12, 17) . Recent studies have shown that Epac participates in cardiac hypertrophy in vitro (28) . In the present study, Rap was involved in PGE 2 stimulation of the hBNP promoter but Ras was not. Thus our data suggest that PGE 2 activates EP 4 , which couples to Rap and B-Raf, resulting in downstream activation of p42/44 MAPK. The question now is whether EP 4 signaling involves Epac and/or PKA activation of Rap.
It is also unclear how p42/44 MAPK activates BNP gene expression. Transcription factors such as Elk-1 and GATA-4 have been reported to mediate hypertrophic gene transcription in cardiac myocytes (29) . In addition, p42/44 MAPK has been shown to activate GATA-4 (45), and GATA-4 activates the hBNP promoter (13) . Because prohypertrophic growth factors and proinflammatory cytokines enhance BNP gene expression by targeting the proximal region of the hBNP promoter, it is likely that GATA-4 is a primary target of PGE 2 action.
In summary, our data indicate that PGE 2 regulates the BNP promoter via EP 4 with downstream activation of the p42/44 MAPK cascade in cardiac myocytes. To our knowledge, these are the first data to demonstrate that PGE 2 enhances BNP gene expression. Our findings support a link between PGE 2 , BNP, and cardiac hypertrophy, which may enable us to better understand the signaling mechanisms underlying the hypertrophic effects of PGE 2 in myocytes.
